German CLL Studygroup

International Workshop on CLL 2025

Paolo Ghia is Professor of Medical Oncology at the Università Vita-Salute San Raffaele, Italy. He is also Deputy Chairman of the Division of Experimental Oncology, at the affiliated hospital, where he is Director of the Strategic Research Program on CLL, which includes a dedicated unit for phase 1 studies.

Stephan Stilgenbauer is Professor of Medicine and Medical Director of the Comprehensive Cancer Center Ulm (CCCU), Head of the Early Clinical Trials Unit (ECTU), and Head of the Division of CLL Dept. of Internal Medicine III at Ulm University, Germany.

An international faculty shares expert insights on current management approaches and emerging developments in CLL and WM, infection prevention and treatment, applications of AI in hemato-oncology, and best practices in patient communication and mental health.

However, in the ALPINE study in relapsed/refractory (R/R) CLL, zanubrutinib demonstrated a better overall response rate (83.5% vs.

European Hematology Association Congress 2026 - Be one step ahead in CLL